Overcoming the Barriers to the Development of Medicines for Ultra Rare Diseases
In the third and final article in the series on Orphan Drugs, Bryan Hurst discusses how to overcome the barriers to the development of medicines for the treatment of ultra-rare diseases. To read the first article on orphan drugs, click here, and for the second article, click here. The decision to invest in developing a […]
Orphan Drug Development
This is the first in a series of articles aiming to highlight the vital role that drug development consultants play in helping small pharma companies to bring new medicines to the market. To put this properly into context it is essential to understand the way drug development has changed. The big pharmaceutical companies that totally […]
